Antonia Salsano
YOU?
Author Swipe
View article: Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris Open
Pityriasis rubra pilaris (PRP) is a rare, papulosquamous, inflammatory skin disease. PRP represents a therapeutic challenge. The rarity of this disease and its possible spontaneous remission makes the conduction and interpretation of thera…
View article: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum] Open
[This corrects the article DOI: 10.2147/CCID.S447123.].
View article: Management of Psoriasis Patients with Serious Infectious Diseases
Management of Psoriasis Patients with Serious Infectious Diseases Open
The management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C, HIV, COVID-19]. Indeed, these infections should be ru…
View article: Risk Factors for Psoriasis Flares: A Narrative Review
Risk Factors for Psoriasis Flares: A Narrative Review Open
Psoriasis is a chronic inflammatory cutaneous disease with multifactorial pathogenesis involving both genetic and environmental factors as well as the innate and acquired immune response. Several triggering factors may exacerbate or worsen…
View article: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab Open
Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide population. Several clinical phenotypes can be distinguished. Among these, erythrodermic psoriasis (EP) is a rare and severe variant (less than 3% o…